TScan Therapeutics is laying off 30% of its workforce as the T-cell receptor (TCR) therapy biotech abandons a phase 1 solid tumor trial and focuses on patients with blood cancers.

Mosti is using Budget 2026 to advance its 'From Lab to Livelihood' agenda as a catalyst for national economic growth and innovation.

By Buertey Francis BORYOR Ghanaian journalists promoting awareness and accurate reporting on agricultural biotechnology have been celebrated at the 2025 OFAB Media Awards (OMAs) held in Accra.

Synthetic biology is ready for the next developmental milestone and America’s leadership depends on getting the financing right.

Licensing remains a dominant model. The value of the licensing-out deals signed by Chinese biotech firms in the first half of ...

A Bay Area biotech company is behind a potentially groundbreaking blood test that promises to be a game-changer in cancer ...

Still, the recently released 2025-30 Arizona Bioscience Roadmap, as well as several academic, community and local government ...

A well-crafted narrative helps investors see not just the molecule in front of them, but the broader therapeutic and ...

The Swiss pharma is paying $12 billion for Avidity Biosciences and its three late-stage antibody oligonucleotide conjugates.

In this GEN interview, Nobel Laureate David Baker, PhD, emphasizes that designing proteins from scratch is reality and unpacks what's needed for AI to transform medicine.

Her name means strong-willed, steeped in creative art. Abhradita Banerjee has lived up to her name, staying steadfast on the ...

Something unusual is happening to biotech stocks: They’re going up. A drug-pricing deal between Pfizer and the White House and a spate of deals have sent the SPDR S&P Biotech exchange-traded fund up 9 ...